These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18771760)

  • 1. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome.
    Canzonetta C; Mulligan C; Deutsch S; Ruf S; O'Doherty A; Lyle R; Borel C; Lin-Marq N; Delom F; Groet J; Schnappauf F; De Vita S; Averill S; Priestley JV; Martin JE; Shipley J; Denyer G; Epstein CJ; Fillat C; Estivill X; Tybulewicz VL; Fisher EM; Antonarakis SE; Nizetic D
    Am J Hum Genet; 2008 Sep; 83(3):388-400. PubMed ID: 18771760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome.
    Lepagnol-Bestel AM; Zvara A; Maussion G; Quignon F; Ngimbous B; Ramoz N; Imbeaud S; Loe-Mie Y; Benihoud K; Agier N; Salin PA; Cardona A; Khung-Savatovsky S; Kallunki P; Delabar JM; Puskas LG; Delacroix H; Aggerbeck L; Delezoide AL; Delattre O; Gorwood P; Moalic JM; Simonneau M
    Hum Mol Genet; 2009 Apr; 18(8):1405-14. PubMed ID: 19218269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.
    Toiber D; Azkona G; Ben-Ari S; Torán N; Soreq H; Dierssen M
    Neurobiol Dis; 2010 Oct; 40(1):348-59. PubMed ID: 20600907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
    Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
    J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
    Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
    Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular Mechanism Underlying Abnormal Differentiation of Neural Progenitor Cells in the Developing Down Syndrome Brain].
    Kurabayashi N; Sanada K
    Yakugaku Zasshi; 2017; 137(7):795-800. PubMed ID: 28674289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
    Hijazi M; Fillat C; Medina JM; Velasco A
    Exp Neurol; 2013 Jan; 239():229-34. PubMed ID: 23124096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function and regulation of Dyrk1A: towards understanding Down syndrome.
    Park J; Song WJ; Chung KC
    Cell Mol Life Sci; 2009 Oct; 66(20):3235-40. PubMed ID: 19685005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells.
    Yabut O; Domogauer J; D'Arcangelo G
    J Neurosci; 2010 Mar; 30(11):4004-14. PubMed ID: 20237271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells.
    Park J; Oh Y; Yoo L; Jung MS; Song WJ; Lee SH; Seo H; Chung KC
    J Biol Chem; 2010 Oct; 285(41):31895-906. PubMed ID: 20696760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
    Çağlayan ES
    Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.
    Najas S; Arranz J; Lochhead PA; Ashford AL; Oxley D; Delabar JM; Cook SJ; Barallobre MJ; Arbonés ML
    EBioMedicine; 2015; 2(2):120-34. PubMed ID: 26137553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
    McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
    Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.
    LaCombe JM; Sloan K; Thomas JR; Blackwell MP; Crawford I; Bishop F; Wallace JM; Roper RJ
    Dis Model Mech; 2024 Sep; 17(9):. PubMed ID: 39136051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells.
    Kurabayashi N; Sanada K
    Genes Dev; 2013 Dec; 27(24):2708-21. PubMed ID: 24352425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.
    Granno S; Nixon-Abell J; Berwick DC; Tosh J; Heaton G; Almudimeegh S; Nagda Z; Rain JC; Zanda M; Plagnol V; Tybulewicz VLJ; Cleverley K; Wiseman FK; Fisher EMC; Harvey K
    Sci Rep; 2019 May; 9(1):7322. PubMed ID: 31086297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYRK1A BAC transgenic mouse: a new model of thyroid dysgenesis in Down syndrome.
    Kariyawasam D; Rachdi L; Carré A; Martin M; Houlier M; Janel N; Delabar JM; Scharfmann R; Polak M
    Endocrinology; 2015 Mar; 156(3):1171-80. PubMed ID: 25490145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.